This study is for people with advanced or metastatic non-small cell lung cancer (NSCLC). It looks at how safe and effective a new drug called datopotamab deruxtecan (Dato-DXd) is when used with immunotherapy, and sometimes with another drug called carboplatin. Immunotherapy helps your immune system fight cancer. Participants will be divided into different groups, called cohorts, to try different doses and combinations of the drugs. First, they will test how much of the drug people can safely take. If that goes well, they will see how the drug works in more people.
Key Points:
- Duration: The study involves multiple cycles of treatment, with initial testing for safety.
- Eligibility: You need to be at least 18 years old, have specific types of lung cancer, and be willing to undergo a tumor biopsy.
- Risks: Possible side effects include issues with the immune system, heart, or other organs.
How understandable was the trial content above?
Hard to understand
Easy to understand